Rituximab therapy achieves comparable remission to cyclophosphamide in ANCA-associated vasculitis with severe KIDNEY involvement

Clicks: 17
ID: 327436
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #30 of 153 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 153 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Introduction The RAVE/RITUXIVAS trials established rituximab (RTX) therapy in ANCA-associated vasculitis (AAV). However, RAVE excluded patients with severe renal involvement (creatinine > 354 µmol/L). Whilst RITUXIVAS did not, treatment included RTX with 2 cyclophosphamide (CYC) pulses. This study reports outcomes in AAV patients with severe renal involvement treated with RTX alone compared to CYC, together with high dose steroids. Methods Data were collected retrospectively for all consecutive AAV presentations with severe renal involvement (peak creatinine >354 µmol/L) between 2010–2023 from two renal units. The primary outcome was sustained remission with independent renal function at 12 months. Results Amongst 107 de novo AAV patients, 66 received pulsed CYC with steroids (39 received plasma exchange (PLEX)), and 41 received RTX with steroids (7 received PLEX). At presentation, there was no significant difference in, renal replacement therapy requirement (CYC, 56% vs RTX, 71%; p = 0.129), peak creatinine (511 vs 538 µmol/L; p = 0.399) or eGFR (9 vs 7 mL/min/1.73m2; p = 0.372). 52% of CYC patients, and 49% of RTX patients met the primary outcome (p = 0.783). At 12 months, there was no significant difference in the proportion of patients with independent renal function (CYC, 65% vs RTX, 56%; p = 0.582), eGFR was similar between CYC and RTX patients (28 vs 31 mL/min/1.73m2, p = 0.439), and 94% of CYC cohort were alive compared to 83% of RTX (p = 0.068). Conclusion RTX with steroids is comparable to CYC with steroids to successfully induce remission in AAV with severe renal involvement.
Reference Key
openalex_W7207579166 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Nishant Chaudhari, Azm Ul Hussain, Lee Quill, Joshua Harridine, Kashif Eqbal, Lorraine Harper, Dimitrios Chanouzas
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag290
URL
https://doi.org/10.1093/ckj/sfag290
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.